EMA started contacting sponsors over unreported trials, and are providing national regulators with the data they need to hold pharma companies, universities and hospitals to account. 
In addition, EMA have pledged a range of other transparency measures, including publicly tracking the number of trial results made public, improving training materials for sponsors,.

Source: Till Bruckner - TRANSPARIMED